| 0.4286 0.005 (1.16%) | 08-27 11:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.67 | 1-year : | 0.81 |
| Resists | First : | 0.58 | Second : | 0.69 |
| Pivot price | 0.47  |
|||
| Supports | First : | 0.39 | Second : | 0.33 |
| MAs | MA(5) : | 0.45 |
MA(20) : | 0.51 |
| MA(100) : | 1.4 |
MA(250) : | 1.54 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 16.8 |
| RSI | RSI(14): 33.7 |
|||
| 52-week | High : | 3.61 | Low : | 0.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CNTX ] has closed above bottom band by 13.0%. Bollinger Bands are 81.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 37 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.44 - 0.44 | 0.44 - 0.45 |
| Low: | 0.41 - 0.41 | 0.41 - 0.42 |
| Close: | 0.42 - 0.42 | 0.42 - 0.43 |
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Fri, 21 Aug 2026
Context Therapeutics Inc. Revenue Breakdown – NASDAQ:CNTX - TradingView
Wed, 12 Aug 2026
Blue Owl Capital Holdings (CNTX) reports 3.19% beneficial stake in Context Therapeutics - Stock Titan
Thu, 06 Aug 2026
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move - Benzinga
Wed, 05 Aug 2026
Context Therapeutics (NASDAQ: CNTX) reports $23.2 million loss and cash runway - Stock Titan
Wed, 05 Aug 2026
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress - GlobeNewswire
Fri, 31 Jul 2026
Context Therapeutics (NASDAQ: CNTX) faces Nasdaq minimum bid-price deficiency risk - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 92 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 69 (%) |
| Shares Short | 5,830 (K) |
| Shares Short P.Month | 3,210 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -76.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -0.9 |
| PEG Ratio | 0 |
| Price to Book value | 1.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|